ClinicalTrials.gg

Keratosis, Actinic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 343 studies for Keratosis, Actinic across more than 10 countries. 30 are recruiting or about to start. 322 of them are mainly about Keratosis, Actinic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
256
Recruiting
22
Status unknown
20
Terminated
15
Active, not recruiting
12
Withdrawn
10

Phase

Phase 3
79
Phase 2
75
Phase 1
50
Phase 4
47
Early Phase 1
5

Where

United States
165
Germany
53
Australia
20
France
17
United Kingdom
15
Netherlands
14

Who develops what

Add Keratosis, Actinic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 3 companies, 4 with this as their studies’ main aim; 1 with a live phase 3 study; 3 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DiclofenacRecent, limited
Evidence
  • NCT05387525 · Almirall, S.A. · Phase 4 · live · comparator · “Diclofenac Sodium 3% Gel” · registered May 2022
  • NCT04552327 · infectopharm arzneimittel gmbh · Phase 3 · comparator · “Solaraze” · registered Sep 2020
  • NCT03826550 · encube ethicals pvt ltd · Phase 3 · comparator · “Solaraze 3% Topical Gel” · registered Jan 2019
  • NCT01453179 · Viatris Inc. · Phase 4 · comparator · “Diclofenac” · registered Sep 2011
  • NCT00777127 · Viatris Inc. · Phase 4 · comparator · “Diclofenac” · registered Oct 2008
Novartis15% of its industry studiesUS: off-patent, 55 generics marketed11 study
FluorouracilEarlier only
Evidence
  • NCT05078827 · encube ethicals pvt ltd · Phase 3 · comparator · “Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.” · registered Sep 2021
  • NCT04875026 · pierre fabre · Phase 4 · background · “5-fluorouracil 4% (Tolak)” · registered Mar 2021
  • NCT03727074 · sol gel technologies ltd · Phase 3 · comparator · “Efudex®” · registered Oct 2018
  • NCT02616601 · Teva Pharmaceutical Industries, Ltd. · Phase 3 · comparator · “Carac® (Fluorouracil) Cream” · registered Nov 2015
Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed00 studies
Diclofenac Sodium GelEarlier onlyPhase 4 trial recorded
Evidence
  • NCT04552327 · infectopharm arzneimittel gmbh · Phase 3 · comparator · “Solaraze” · registered Sep 2020
  • NCT03826550 · encube ethicals pvt ltd · Phase 3 · comparator · “Solaraze 3% Topical Gel” · registered Jan 2019
  • NCT02952898 · Balmoral Medical company · Phase 3 · comparator · “Diclofenac Sodium Gel, 3%” · registered Oct 2016
Novartis25% of its industry studies00 studies

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.HW211026 · Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Phase 2 main aimNCT07513454 A Phase 2 Study of HW211026 — primary endpoint: Complete Clearance Rate · 80 enrolled
  • Jan 2027 est.Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20% · Sun Pharmaceutical Industries Limited · Phase 3 main aimNCT07144345 Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp — primary endpoint: Complete Clearance Rate (CCR) i.e., proportion of patients achieving complete clearance of all AK lesions in the Treatment Area. · 160 enrolled
  • Jan 2027 est.Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20% · Sun Pharmaceutical Industries Limited · Phase 3 main aimNCT07144852 Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities — primary endpoint: Complete Clearance Rate (CCR) i.e., proportion of patients achieving complete clearance of all AK lesions in the Treatment Area) · 260 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Keratosis, Actinic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimitotic agents 1 open · NSAIDs 12 · COX-2 inhibitors 4

Coming up

10studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10, phase 3 first

Who these studies take

Of the 22 Keratosis, Actinic studies recruiting now, 17 (77%) set no upper age limit and 1 (5%) stop at 75 or younger. 1 (5%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (9%) take healthy volunteers.

Recruiting studies that take each age, of 22
AgeWomenMen
101 (5%)1 (5%)
1819 (86%)19 (86%)
3019 (86%)19 (86%)
4019 (86%)19 (86%)
5019 (86%)19 (86%)
6521 (95%)21 (95%)
7521 (95%)21 (95%)
8521 (95%)21 (95%)

Across all 343 studies, recruiting or not: 5% stop at 75 or younger and 2% at 65; 3% take children; 1% are for women only and 1% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Keratosis, Actinic studies take

Of 26 phase 3 interventional studies under Keratosis, Actinic, half reached primary completion within 13 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 210 mo9–18 · 18 studies——
Phase 313 mo7–22 · 26 studies——
Phase 412 mo8–30 · 19 studies——
Interventional, no phase19 mo12–33 · 33 studies——
Observational22 mo11–36 · 17 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 343. Browse all 343 → or search them.